Why the study?
Does mivazerol reduce rates of myocardial infarction or cardiac death in patients with known coronary heart disease undergoing noncardiac surgery?
Does mivazerol reduce rates of myocardial infarction or cardiac death in patients with known coronary heart disease undergoing noncardiac surgery?
Mivazerol did not reduce perioperative MI or cardiac death in patients with coronary heart disease undergoing noncardiac surgery, though it may offer protection in the vascular surgery subgroup.
Mivazerol lacks support for routine perioperative use in CHD patients; challenges efficacy assumptions and leaves vascular surgery benefit open for study.
The alpha2-adrenergic agonist, mivazerol, did not alter the rates of myocardial infarction or cardiac death in patients with known coronary heart disease undergoing noncardiac surgery. However, it may have protected patients undergoing vascular surgery from further coronary events, and a specific study of such patients is now indicated.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (1999) studied this question.